CONTENTS

RESEARCH

Estimated Blood Loss in Open Heart Surgery
(Taksiran Kehilangan Darah di Bedah Jantung Terbuka)
Riesti Ekasanti, Rachmawati Muhiddin, Mansyur Arif
.......................................................................................................................... 205–207

Error Rate of Disc Diffusion Method in Ceftazidime/Cefotaxime Susceptibility Test on Clinical Isolates of Klebsiella Pneumoniae
(Laju Kesalahan Uji Kepekaan Ceftazidim/Cefotaxime Metode Difusi Cakram pada Klebsiella Pneumoniae)
Luz Maria GBW, Osman Sianipar, Usi Sukorini
........................................................................................................ 208–211

Correlation of Monocyte Count, MLR and NLCR with Presepsin Level in SIRS
(Hubungan Jumlah Monosit, MLR dan NLCR dengan Kadar Presepsin pada SIRS)
Nurmalia PS, N. Suci W, Imam BW
............................................................................................................................... 212–218

Role of Signal Transduction ERK1/2 on the Proliferation of Endothelial Progenitor Cell (EPC) of Patients with Stable Angina Pectoris Induced by Growth Factors
(Peran Transduksi Sinyal ERK1/2 terhadap Proliferasi Endothelial Progenitor Cell (EPC) Pasien Angina Pektoris Stabil yang Diinduksi oleh Faktor Pertumbuhan)
Yudi Her Oktaviono, Djanggan Sargowo, Mohammad Aris Widodo, Yanni Dirgantara, Angliana Chouw, Ferry Sandra
...................................................................................................................................... 219–226

Analysis of Mean Platelet Volume in Type II Diabetic Patients with Vascular Complication
(Analisis Mean Platelet Volume Pasien Diabetes Melitus Tipe II Komplikasi Vaskuler)
Mustakin, Liong Boy Kurniawan, Nurahmi, Ruland DN Pakasi
.......................................................................... 227–231

The Automatic Microdilution-Broth in Sensitivity Testing of Acinetobacter Baumannii Isolates
(Microdilution-Broth Otomatis dalam Uji Kepekaan Isolat Acinetobacter Baumannii)
Dyah Artini, Osman Sianipar, Umi S Intansari
........................................................................................................ 232–236

Interleukin-8 Related with Bone Mineral Density
(Interleukin-8 terhadap Kepadatan Mineral Tulang)
Yurdiansyah Latif, Ulenq Bahrun, Ruland Pakasi
.................................................................................................... 237–240

The Risk Factor of Alloantibody Formation in Thalassemia Patients Receiving Multiple Transfusion
(Faktor Kebahayaan Terbentuknya Aloantibodi pada Pasien Talasemia yang Menerima Transfusi Darah Berulang)
Veronica Fridawati, Teguh Triyono, Usi Sukorini
.................................................................................................... 241–245

Specific IgE Immunoblot Method in Allergic Rhinitis
(IgE Spesifik Menurut Metode Imunoblot di Rinitis Alergi)
Izzuki Muhashonah, Aryati, Dwi Reno Pawarti, M. Robi’ul Fuadi, Janti Trihabsari
............................................................................................................................. 246–253

Metabolic Syndrome Among Adults in Rural Areas
(Sindrom Metabolik pada Dewasa di Daerah Pedesaan)
Fenty, Widayati A, Virginia DM, Hendra P
...................................................................................................................... 254–257
Glycated Albumin and HbA1c in Diabetic Nephropathy
*(Albumin Glikat dengan HbA1c dan Penyakit Nefropati Diabetik)*
**Elvan Dwi Widyadi, Jusak Nugraha, Ferdy Royland Marpaung** ................................................................. 258–262

Small Dense Low Density Lipoprotein with Angiographically Atherosclerosis in Coronary Heart Disease
*(Small Dense Low Density Lipoprotein dengan Aterosklerosis Secara Angiografi di Penyakit Jantung Koroner)*
**Yuliani Zalukhu, Siti Muchayat Purnamaningsih, Nahar Taufik, Suwarso** .......................................................... 263–267

Total IgG and IgG Anti PGL-I with Duration of Therapy and Reactions of Multibaciller Leprosy
*(Jumlah Keseluruhan IgG dan IgG Anti PGL-I Mycobacterium leprae dengan Lama Pengobatan dan Reaksi Kusta Multibasiler)*
**Endang Retnowati, Halik Wijaya, Indropo Agusni** ......................................................................................................................................... 268–273

Factors in Acute Transfusion Reaction
*(Faktor Reaksi Transfusi Darah Akut)*
**Wiwi Payung, Rachmawati AM, Mansyur Arif** ........................................................................................................ 274–278

Neopterin and CD4+ T-Lymphocytes in Stage I HIV Infection
*(Neopterin dan Limfosit T-CD4+ di Infeksi HIV Stadium I)*
**Harianah, Endang Retnowati, Erwin Astha Triyono**.................................................................................................................................................. 279–283

LITERATURE REVIEW

The Role of Platelets SCD40L to Atherogenesis
*(Peran sCD40L Trombosit terhadap Aterogenesis)*
**Liong Boy Kurniawan** ...................................................................................................................................................... 284–288

CASE REPORT

Multiple Myeloma in a Young Adult
*(Mieloma Multipel di Dewasa Muda)*
**Hendra Rasubala, Agus Alim Abdullah, Mansyur Arif** ......................................................................................................... 289–292
LITERATURE REVIEW

THE ROLE OF PLATELETS SCD40L TO ATHEROGENESIS
(Peran sCD40L Trombosit terhadap Aterogenesis)

Liong Boy Kurniawan

ABSTRACT

The role of CD40 and CD40L in the maturation and differentiation of B lymphocyte cells has been previously described. CD40L is also expressed by other cells such as macrophages, dendrite cells, neutrophils and endothelial cells. Platelets are also proven to express CD40L and can release it into a soluble form, known as sCD40L. This review was aimed to the role of sCD40L produced by platelets in the atherogenesis process. Explain through the interaction with other molecules such as OxLDL, sCD40L may cause endothelial dysfunction, ROS releasing, increased activity of ICAM, VCAM and MMP, platelets activation and plaque destabilization. Atherogenesis can be triggered by sCD40L interaction. Findings in the pharmacology and other aspects need to be studied to inhibit sCD40L in the atherogenesis process. Further in depth research is required to prove the role of sCD40L as a predictor of atherogenesis.

Key words: sCD40L, platelets, atherogenesis

INTRODUCTION

Cluster of Differentiation (CD) 40 is a molecule that was originally discovered to play a role of the humoral immune system. This molecule was first identified in 1985 and is expressed at all stages of cell maturation and differentiation of B lymphocytes. On the other hand, CD40L ligand is mainly expressed in activated T CD4+. 1 CD40 is also expressed on a number of other cells such as epithelial cells, fibroblasts, smooth muscle cells and platelets. CD40 expression is induced by proinflammatory stimuli such as Interleukin (IL) 1, 3, 4, Tumor Necrosis Factor Alpha (TNF-α) and interferon-γ.2-3 Oxidized Low Density Lipoprotein (oxLDL) also induces CD40L gene expression.4 CD40 is a type I transmembrane protein receptor and is included in the tumor necrosis factor super family. This molecule is encoded in chromosome 20 (q12-q13.2).5 The gene that encodes CD40L lies in the X chromosome in position Xq26.3-Xq27.1 with the length of deoxynucleotide acid (DNA) at 12-13kb and has five exons.6 This molecule is a type 2 transmembrane and included in the same superfamily as CD40,7 Another name of CD40L is CD154 which has a size of 39 kD and can be transformed into a soluble form with a size of 18 kD.8 Soluble CD40L (sCD40L) still has the ability to bind the CD40 receptor and is believed to be biologically active.9 The interaction between CD40 and CD40L is originally known as a co-
The Role of Platelets SCD40L to Atherogenesis - Kurniawan

**DISCUSSION**

Numerous studies have demonstrated the role of sCD40L in cardiovascular incidence. A prospective study in a group of middle-aged females with the risk of cardiovascular for 4 years found that females with a level of sCD40L over the percentile of 95 (> 3.71 ng/mL) had a 3.3 times risk of suffering from cardiovascular disease in the future. Another study comparing the expression of CD40L/CD154 and sCD40L/CD154 level in patients with acute myocardial infarction, unstable angina and stable angina found that the expression of CD40L/CD154 on platelets and sCD40L/CD154 increased in patients with unstable angina and myocardial infarction. Similar findings were also reported previously in which the levels of membrane-bound sCD40L and CD40L were higher in patients with angina, especially unstable. The results of the research involving 880 patients with atrial fibrillation connecting sCD40 to stroke found that sCD40L level was not related to the risk and course of the stroke with the group. This probably reflects the role of platelet activation that is limited to thrombogenesis due to atrial fibrillation. Similar findings were also reported previously in which the levels of membrane-bound sCD40L and CD40L were higher in patients with angina, especially unstable. The results of the research involving 880 patients with atrial fibrillation that related sCD40 to stroke found that sCD40L level was not related to the risks and course of stroke in the group. This probably indicated the role of platelet activation that was limited to thrombogenesis due to atrial fibrillation.

In a particular research involving micro particles of human atherosclerotic plaques that expressed CD40L and stimulated endothelial cell proliferation after ligation of CD40 and triggered angiogenesis in vivo. Stimulation of platelets with recombination of sCD40L triggered the expression of M.RNA platelet aggregation and conjugation of platelets and leukocytes. The platelets isolated from CD40L deficient mice showed a decrease in the release of nitric oxide compared to the one from wild-type mice. A report said that the level of sCD40L in blood components was higher than in fresh blood plasma. The highest levels of sCD40L were found in the sample of platelet concentrates from apheresis, followed by platelet concentrates from whole blood and the one from packed red blood cells.

Patients with Diabetes Mellitus (DM) type 1 and 2 had higher levels of sCD40L than the comparison. The high level of SCD40L was associated with in vitro adhesion molecules, the release of Monocyte Chemo-Attractant Protein-1 (MCP-1), impaired endothelial cell migration as well as increased O2- resulted from monocytes. scD40L level and soluble P-selectin were used as an index of platelet activation, IL-6 served as proinflammatory cytokines and tissue factor which acted as the coagulation initiator which overall was higher in patients with DM type 2 than the comparison. Intervention in diabetic group lowered sCD40L level significantly. The administration of thiazolidinedione for 12 weeks lowered sCD40L level up to 29% in patients with DM. In the randomized, double blind study involving 110 patients with familial hypercholesterolemia treated with atorvastatin 80 mg/
day or simvastatin 40 mg/day for two (2) years showed a decrease in sCD40L level up to 40%.24

The pivotal role of CD40/CD40L in the development of atherosclerotic plaque was shown in LDL receptor-deficient mice fed a high cholesterol diet. The formation and progress of the atherosclerotic lesion were suddenly reduced by interrupting the signaling of CD40 in the mice using a neutralizing anti-CD40L antibody.25 Initial trigger of the expression of CD40/CD40L in atheroma was still unclear but several studies showed that oxidized LDL likely played a role in this process. Oxidized LDL induced the expression of CD40 and CD40L in endothelial cells, smooth muscle and macrophage in human.26 The signal of CD40/CD40L in endothelial cells stimulated the results of Reactive Oxygen Species (ROS), inhibited the results of endothelial Nitric Oxide (NO) and caused disruption to the function.26

The CD40 ligation to endothelial cells and smooth muscle induced the expression of adhesion molecules such as E-selectin, Vascular Cell adhesion Molecule1 (VCAM-1), intercellular adhesion Molecule1 (ICAM-1), which increased the recruitment of monocytes and lymphocytes to the lesion.27 Leukocytes recruitment was then accelerated by the secretion of MCP-1, IL-1, IL-6 and TNF-α induced by CD40L.2,3 CD40L in activated platelets could trigger inflammatory reactions expressing endothelial cells, which induced secretion of chemokines, the expressed adhesion molecule, increased recruitment and extravazation of leukocytes to the site of lesion.28 A variety of cells expressing CD40 and or CD40L are shown in Table 1.

The platelets which expressed CD40 in a resting and activated state, or when CD40L was activated. sCD40L released by platelets during thrombosis had three (3) roles of process namely: inflammation through the product and release of proinflammatory cytokines from vascular cells and metalloproteinases matrix derived from cells, thrombosis by stabilizing the thrombus rich in platelets as well as restenosis by inhibiting reendothelisation injured blood vessels, resulting in the activation and proliferation of smooth muscle cells (see Figure 2).29

CD40L is not expressed in resting platelets, but will quickly be expressed once the platelets are activated. Expressed CD40L on the surface of platelets generally will be released after a period of several minutes to several hours to form soluble in trimeric form called sCD40L. Some of the compounds that can activate platelets include adenosine diphosphate, thrombin and collagen. The translocation of CD40L takes place along with the release of granule α contents including Platelet Derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF-β), Platelet Factor 4 (PF4) and thrombospondin (TSP). Antagonist GPIIb/IIIa

Table 1. A variety of cells that express CD40 and CD40L

<table>
<thead>
<tr>
<th>Type of expressing cell</th>
<th>CD40</th>
<th>CD40L</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4 T cells</td>
<td>(-)</td>
<td>(+++)</td>
</tr>
<tr>
<td>B cells</td>
<td>(++)</td>
<td>(++)</td>
</tr>
<tr>
<td>Macrophages</td>
<td>(+)</td>
<td>(+)</td>
</tr>
<tr>
<td>Platelets</td>
<td>(+)</td>
<td>(+)</td>
</tr>
<tr>
<td>Dendritic cells</td>
<td>(-)</td>
<td>(+)</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>(+)</td>
<td>(+)</td>
</tr>
<tr>
<td>Endothelial cells</td>
<td>(+)</td>
<td>(+)</td>
</tr>
</tbody>
</table>

Figure 2. Three roles of sCD40L after being released from platelets during the modification of thrombosis29

Figure 3. Process of releasing sCD40L in platelets stimulation, modification29
The Role of Platelets SCD40L to Atherogenesis - Kurniawan. 287

inhibits hydrolysis and the release of sCD40L from platelets (Figure 3).

Some reports showed that more than 95% of CD40L circulating was derived from platelets. Vascular endothelial cells, smooth muscle and macrophages in human increased the expression of matrix metalloproteinase (MMP) by ligation of CD40 including MMP-1, MMP-8 and MMP-13. CD40 also made the plaque vulnerable by inducing the expression of tissue factor both in endothelial cells and smooth muscle. The increased level of TF triggered thrombogenic power in lesion rupturing through the extrinsic pathway of blood coagulation. The process related to the role of sCD40L on the incidence of atherosclerosis is shown in Figure 4.

CONCLUSION

CD40L is expressed primarily on activated platelet cells other than playing a role in cueing T cells. The interaction with CD40 molecules plays a great role in atherosclerosis. CD40L expressed on platelets will experience the release and will form compounds soluble in the blood plasma called sCD40L. sCD40L is proven to play a great role in inflammation and atherogenity through interaction with various factors such as: oxLDL. Further process will lead to: impaired endothelial function, release of ROS, increased activity of ICAM, VCAM and MMP, as well as platelets and plaque destabilization.

The studies on drugs that reduce the expression and release of sCD40L on platelets and inhibit the function are required given the important role of sCD40L in atherogenesis. Further studies on various other factors, in addition to drugs that can suppress the amount of sCD40L which will ultimately reduce the risk of atherosclerosis are also required. Further and in depth research on the role of sCD40L as a marker for atherogenesis also needs to be applied in the laboratory medicine.

REFERENCES


